华人健康
(301408)
| 流通市值：21.69亿 | | | 总市值：58.16亿 |
| 流通股本：1.49亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,266,847,107 | 4,531,692,295.23 | 3,269,282,916.66 | 2,167,417,364.99 |
| 营业收入 | 1,266,847,107 | 4,531,692,295.23 | 3,269,282,916.66 | 2,167,417,364.99 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 1,175,205,083.11 | 4,323,588,684.51 | 3,133,754,849.95 | 2,072,607,532.09 |
| 营业成本 | 841,486,683.18 | 3,053,593,919.21 | 2,209,430,174 | 1,476,841,935.6 |
| 利息支出 | - | 0 | - | 0 |
| 手续费及佣金支出 | - | 0 | - | 0 |
| 退保金 | - | 0 | - | 0 |
| 赔付支出净额 | - | 0 | - | 0 |
| 提取保险合同准备金净额 | - | 0 | - | 0 |
| 保单红利支出 | - | 0 | - | 0 |
| 分保费用 | - | 0 | - | 0 |
| 税金及附加 | 5,081,878.39 | 23,751,912.77 | 15,612,408.1 | 10,227,955.2 |
| 销售费用 | 261,295,611.45 | 997,770,391.32 | 728,529,767.28 | 467,504,701.63 |
| 管理费用 | 56,332,622.12 | 194,391,170.65 | 141,170,914.53 | 92,504,960.96 |
| 研发费用 | 6,522,397.24 | 29,387,268.49 | 21,099,674.53 | 15,401,262.49 |
| 财务费用 | 4,485,890.73 | 24,694,022.07 | 17,911,911.51 | 10,126,716.21 |
| 其中:利息费用 | 3,593,556.23 | 14,517,322.94 | 12,987,925.89 | 6,472,401.11 |
| 其中:利息收入 | 3,658,147.35 | 15,558,356.44 | 11,114,680.83 | 8,900,804.58 |
| 加:公允价值变动收益 | - | 0 | 387.7 | 0 |
| 加:投资收益 | 348,798.93 | 1,618,812.17 | 1,251,299.74 | 634,983.53 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | 0 | - | 0 |
| 资产处置收益 | 915,251.57 | 2,718,324.01 | 2,073,118.56 | 831,072.31 |
| 资产减值损失(新) | -8,480,253.97 | -27,487,722.98 | -5,237,593.08 | -4,809,086.7 |
| 信用减值损失(新) | -2,789,737.53 | -1,000,929.87 | -4,081,720.74 | -1,968,677.97 |
| 其他收益 | 2,747,921.99 | 23,972,667.36 | 19,569,312.01 | 13,234,419.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 84,384,004.88 | 207,924,761.41 | 149,102,870.9 | 102,732,543.38 |
| 加:营业外收入 | 223,386.74 | 1,022,213.64 | 879,748.68 | 340,795.62 |
| 减:营业外支出 | 1,050,271.83 | 3,475,909.38 | 1,765,553.78 | 1,005,274.33 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 83,557,119.79 | 205,471,065.67 | 148,217,065.8 | 102,068,064.67 |
| 减:所得税费用 | 18,473,171.52 | 53,211,960.36 | 32,350,773.59 | 22,254,311.98 |
| 六、净利润 | 65,083,948.27 | 152,259,105.31 | 115,866,292.21 | 79,813,752.69 |
| 持续经营净利润 | 65,083,948.27 | 152,259,105.31 | 115,866,292.21 | 79,813,752.69 |
| 终止经营净利润 | - | 0 | - | - |
| 归属于母公司股东的净利润 | 61,222,277.52 | 137,699,528.81 | 107,929,607.48 | 72,969,838.3 |
| 少数股东损益 | 3,861,670.75 | 14,559,576.5 | 7,936,684.73 | 6,843,914.39 |
| (一)基本每股收益 | 0.15 | 0.34 | 0.27 | 0.18 |
| (二)稀释每股收益 | 0.15 | 0.34 | 0.27 | 0.18 |
| 八、其他综合收益 | - | 334,330 | 300,897 | - |
| 归属于母公司股东的其他综合收益 | - | 334,330 | 300,897 | - |
| 九、综合收益总额 | 65,083,948.27 | 152,593,435.31 | 116,167,189.21 | 79,813,752.69 |
| 归属于母公司股东的综合收益总额 | 61,222,277.52 | 138,033,858.81 | 108,230,504.48 | 72,969,838.3 |
| 归属于少数股东的综合收益总额 | 3,861,670.75 | 14,559,576.5 | 7,936,684.73 | 6,843,914.39 |
| 公告日期 | 2025-04-29 | 2025-04-25 | 2024-10-29 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |